GLP-1 and FGF21 double-factor high-expression adipose-derived stem cell virus residue detection method

Through real-time fluorescence quantitative PCR technology, specific gag gene primers and probes are used to solve the problem of virus residue detection in the treatment of GLP-1 and FGF21 two-factor modified cell, achieving efficient and reliable virus residue detection, ensuring diabetic cells The safety and effectiveness of therapeutic products.

CN119040515APending Publication Date: 2024-11-29BEIJING JIYUAN BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410676727.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-29
Filing Date
2024-05-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing diabetes cell therapy products lack high-specificity, reliability and low detection limits in the assessment of safety, effectiveness and stability of diabetic cell therapy products, especially between GLP-1 and FGF21 bifactor modified autologous fats In the treatment of serum stem cells.

Method used

Real-time fluorescence quantitative PCR technology is used to design specific gag gene primers and probes to monitor the fluorescent signals of viral core proteins, and efficient detection of virus residues is achieved, ensuring low detection limits and strong specificity.

Benefits of technology

It realizes efficient detection of the residual of high-expression adipose stem cell virus of GLP-1 and FGF21 bifactor, ensures the safety and effectiveness of the therapeutic product, and provides a reliable evaluation system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a GLP-1 and FGF21 double-factor high-expression adipose-derived stem cell virus residue detection method, which adopts real-time fluorescent quantitative PCR (polymerase chain reaction), utilizes fluorescence signal accumulation to monitor the whole PCR process and gag gene encoding virus core proteins such as nucleocapsid protein, inner membrane protein and capsid protein in real time, and by designing a specific gag gene primer and an amplification reagent, the GLP-1 and FGF21 double-factor high-expression adipose-derived stem cell virus residue detection method can detect the GLP-1 and FGF21 double-factor high-expression adipose-derived stem cell virus residue. The purpose of detecting virus residues can be achieved by adopting a real-time fluorescent quantitative PCR method, the efficiency is high, the specificity is strong, and the detection limit is low.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for detecting virus residues in gene-modified cells, and in particular to a method for detecting virus residues in adipose stem cells with high expression of GLP-1 and FGF21 dual factors. Background Art

[0002] In order to solve the current situation of single clinical treatment mode and poor effect of diabetes, the applicant, based on the extensive research results of mesenchymal stem cell treatment of diseases, innovatively introduced GLP-1 and FGF21 into autologous adipose mesenchymal stem cells, such as 201810283803.0 and 202010180799.2, to obtain a cell therapy product for type 2 diabetes.

[0003] In order to explore the safety, efficacy and stability evaluation system of cell therapy products for the treatment of type 2 diabetes mellitus using autologous adipose-derived mesenchymal stem cells modified with GLP-1 and FGF21, it is necessary to develop a method for detecting viral residues with strong specificity, high reliability and low detection limit. Summary of the invention

[0004] The present invention utilizes real-time fluorescence quantitative PCR and utilizes the accumulation of fluorescence signals to monitor the entire PCR process in real time. The gag gene encodes core proteins of the virus, such as nucleocapsid protein, inner membrane protein and capsid protein, etc. By designing specific gag gene primers and amplification reagents, the purpose of detecting virus residues can be achieved by using the real-time fluorescence quantitative PCR method, which has high efficiency, strong specificity and low detection limit, thereby completing the present invention.

[0005] The method for detecting virus residues in adipose stem cells with high expression of both GLP-1 and FGF21 provided by the present invention detects whether the virus remains by using real-time fluorescence quantitative PCR with gag gene primers.

[0006] In the method of the present invention, the gag gene primers are selected from one or more pairs of the following primers:

[0007] Ⅰ:

[0008] Upstream primer: 5'-CCCATGTTTTCAGCATTATCAG-3'

[0009] Downstream primer: 5′-GTCACTTCCCCTTGGTTCTC-3′;

[0010] Ⅱ:

[0011] Upstream primer: 5'-GGGAGCTAGAACGATTCGCA-3'

[0012] Downstream primer: 5′-TGGGGTGGCTCCTTCTGATA-3′;

[0013] III:

[0014] Upstream primer: 5'-AGCGTCAGTATTAAGCGGGG-3'

[0015] Downstream primer: 5′-TGCGAATCGTTCTAGCTCCC-3′;

[0016] IV:

[0017] Upstream primer: 5'-GGAAGATCTGGCCTTCCCAC-3'

[0018] Downstream primer: 5′-TTATTGTGACGAGGGGTCGC-3′;

[0019] V:

[0020] Upstream primer: 5'-GGTGCGAGAGCGTCAGTATT-3'

[0021] Downstream primer: 5′-CAGGCCAGGATTAACTGCGA-3′;

[0022] VI:

[0023] Upstream primer: 5'-TATCAGAAGGAGCCACCCCA-3'

[0024] Downstream primer: 5′-CTGGGTTCGCATTTTGGACC-3′;

[0025] VII:

[0026] Upstream primer: 5'-ACAGCAATCAGGTCAGCCAA-3'

[0027] Downstream primer: 5′-GGTTCTCTCATCTGGCCTGG-3′;

[0028] VIII:

[0029] Upstream primer: 5'-ACTCTAAGAGCCGAGCAAGC-3'

[0030] Downstream primer: 5′-CCTTGTCTATCGGCTCCTGC-3′;

[0031] IX:

[0032] Upstream primer: 5'-AAAAAGCACAGCAAGCAGCA-3'

[0033] Downstream primer: 5′-AAATCTTGTGGGGTGGCTCC-3′;

[0034] Ⅹ:

[0035] Upstream primer: 5'-GGCTTTCAGCCCAGAAGTGA-3'

[0036] Downstream primer: 5′-TCCCATTCTGCAGCTTCCTC-3′;

[0037] Ⅺ:

[0038] Upstream primer: 5'-CCAGGCCAGATGAGAGAACC-3'

[0039] Downstream primer: 5′-CCTAGGGGCCCTGCAATTTT-3′.

[0040] More preferably, the gag gene primer is the following primer:

[0041] Ⅰ:

[0042] Upstream primer: 5'-CCCATGTTTTCAGCATTATCAG-3' (gag-F)

[0043] Downstream primer: 5'-GTCACTTCCCCTTGGTTCTC-3' (gag-R).

[0044] In the present invention, it is preferred to use a probe selected from the following:

[0045] 5'FAM-AAATCTTGTGGGGTGGCTCCTT-3';

[0046] 5'-FAM-AACATCAGAAGGCTGTAGACAAATA-3';

[0047] 5'-FAM-AAATTAAAACATATAGTATGGGCAA-3';

[0048] 5'-FAM-AGCAGACCAGAGCCAACAGCCCCAC-3';

[0049] 5'-FAM-ATATAGTATGGGCAAGCAGGGAGCT-3';

[0050] 5'-FAM-ACATCAAGCAGCCATGCAAATGTTA-3';

[0051] 5'-FAM-CTATAGTGCAGAACATCCAGGGGCA-3';

[0052] 5'-FAM-GATGACAGAAACCTTGTTGGTCCAA-3';

[0053] 5'-FAM-CAGGACACAGCAATCAGGTCAGCCA-3';

[0054] 5'-FAM-AGCATTATCAGAAGGAGCCACCCCA-3';

[0055] 5'-FAM-CAGGAACTACTAGTACCCTTCAGGA-3';

[0056] More preferably, the following probes are selected for use:

[0057] 5'FAM-AAATCTTGTGGGGTGGCCTCCTT-3'BHQ1(gag-P).

[0058] In the method of the present invention, real-time fluorescence quantitative PCR is performed using a kit, preferably an AceQ UniversalU+Probe Master Mix V2 kit, a TaqMan TM OpenArray TM Real-Time PCR Master Mix Kit or One Step PrimeScript TM RT-PCR Kit (Perfect Real Time), more preferably AceQ Universal U+Probe Master Mix V2 kit.

[0059] In the method of the present invention, real-time fluorescence quantitative PCR is preferably performed at 1×10 7 ~1×10 1 copies / μl range.

[0060] The method for detecting virus residues in adipose stem cells with high expression of both GLP-1 and FGF21 provided by the present invention has high specificity and low detection limit by selecting specific gag gene primers and amplification reagents. DETAILED DESCRIPTION

[0061] The present invention is further described below by way of examples. However, it should be understood by those skilled in the art that the examples are only used to illustrate the present invention and do not constitute any limitation to the present invention.

[0062] Unless otherwise specified, the experiments and methods described in the examples were performed in accordance with conventional methods well known in the art and described in various references. If no specific conditions are specified in the examples, the experiments were performed according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be obtained commercially.

[0063] 1. Main reagents and consumables (Examples 1 and 2)

[0064]

[0065]

[0066] 3. Instruments and Equipment (Examples 1 and 2)

[0067]

[0068]

[0069] Example 1: Method Applicability Study

[0070] Overview: The quantitative standard was diluted 10 times to different concentrations. The amplification efficiency of the standard curve was analyzed through the test results of the samples to explore the scope of application of the method.

[0071] 1. Preparation of standard solution

[0072] The quantitative standard (1.8483 mg / ml, 8847 bp, can be converted to 1.91×10 11 copies / μl) were diluted according to the following table.

[0073] serial number Dilution method Concentration (copies / μl) A 10μl of quantitative standard + 9.1μl Nuclease-Free Water <![CDATA[1×10 11 ]]> B <![CDATA[10μl of 1×10 11 +90μl Nuclease-Free Water]]> <![CDATA[1×10 10 ]]> C <![CDATA[10μl of 1×10 10 +90μl Nuclease-Free Water]]> <![CDATA[1×10 9 ]]> D <![CDATA[10μl of 1×10 9 +90μl Nuclease-Free Water]]> <![CDATA[1×10 8 ]]> ST1 <![CDATA[10μl of 1×10 8 +90μl Nuclease-Free Water]]> <![CDATA[1×10 7 ]]> ST2 <![CDATA[10μl of 1×10 7 +90μl Nuclease-Free Water]]> <![CDATA[1×10 6 ]]> ST3 <![CDATA[10μl of 1×10 6 +90μl Nuclease-Free Water]]> <![CDATA[1×10 5 ]]> ST4 <![CDATA[10μl of 1×10 5 +90μl Nuclease-Free Water]]> <![CDATA[1×10 4 ]]> ST5 <![CDATA[10μl of 1×10 4 +90μl Nuclease-Free Water]]> <![CDATA[1×10 3 ]]> ST6 <![CDATA[10μl of 1×10 3 +90μl Nuclease-Free Water]]> <![CDATA[1×10 2 ]]> ST7 <![CDATA[10μl of 1×10 2 +90μl Nuclease-Free Water]]> <![CDATA[1×10 1 ]]>

[0074] 2. No template control NTC

[0075] Nuclease-Free Water was used as a no-template control.

[0076] 3. Preparation of Negative Control NCS

[0077] 200 μl PBS was added to the NCS tube as a negative control (cells without genetic modification) for extraction. The negative control NCS was pre-treated with the samples of the same batch to prepare a negative control NCS purified solution.

[0078] 4. PCR reaction system configuration

[0079] Calculate the number of reaction wells required based on the number of positive controls, no-template controls and samples to be tested, and make 2 replicate wells / sample. Number of reaction wells = (1 no-template control NTC + 1 negative control NCS + sample to be tested) × 2

[0080] Calculate the total amount of qPCR MIX required according to the following table: qPCR MIX = (number of reaction wells + 2) × 12 μl (including the loss amount of 2 wells)

[0081] qPCR MIX

[0082] Reaction liquid composition Volume (μl) AceQ U+Universal Probe Master Mix(2×) 10 Upstream primer gag-F (10 μM) 0.8 Downstream primer gag-R (10 μM) 0.8 Probe gag-P (10 μM) 0.4 Total 12

[0083] 5. Add sample

[0084] Melt each reagent on ice, shake gently to mix, and add samples as shown in the table below.

[0085] Add sample to each reaction well

[0086] No template control NTC 12μl qPCR MIX+8μl Nuclease-Free Water Standards to be tested 12μl qPCR MIX + 8μl standard to be tested

[0087] 6. PCR reaction conditions

[0088]

[0089] 7. Results

[0090] Data Summary

[0091]

[0092] It can be seen from the above table that in 1×10 7 ~1×10 1 The PCR amplification efficiency of this method is good within the range of copies / μl, and it can be used as a method for detecting virus residues.

[0093] Example 2: Specificity and detection limit study

[0094] Overview: Dilute the quantitative standard to a certain range, and extract DNA from negative and positive cell samples for detection.

[0095] 1. Preparation of standard solution

[0096] Refer to Example 1, 1. Preparation of standard solution.

[0097] 2. Preparation of Negative Control NCS

[0098] Add 200 μl PBS to the NCS tube as a negative control for extraction. The negative control NCS is pre-treated with the samples of the same batch to prepare the negative control NCS purified solution.

[0099] 3. Sample Extraction and Purification

[0100] (1) Take low adsorption centrifuge tubes and mark them as S and NC. Add 2×10 6 Cell suspension of 10 cells (positive cells to be detected, adipose stem cells modified by GLP-1 and FGF21 dual factors, prepared according to Example 201810283803.0), NC tube added 2×10 6 The uninfected negative cell suspension (negative control, adipose stem cells without genetic modification) was centrifuged at 300 rcf for 1 min, the supernatant was removed, 200 μl PBS was added, and the cells were shaken until they were completely suspended.

[0101] (2) Add 20 μl of proteinase K and vortex to mix for 15 seconds.

[0102] (3) Add 200 μl of buffer AL, vortex mix for 15 seconds, incubate at 56°C for 10 minutes, and centrifuge for 10 seconds to remove the liquid on the tube cap.

[0103] (4) Add 200 μl of ethanol, vortex and mix for 15 seconds, then centrifuge. Transfer the mixed liquid to a filter column and centrifuge at 25°C, 6000 rcf, for 1 min.

[0104] (5) Replace with a new 2 ml collection tube, place the filter column in (4), add 500 μl AW1 washing solution, centrifuge at 25°C, 20,000 rcf, for 1 min.

[0105] (6) Replace with a new 2 ml collection tube, place in the filter column in (5), add 500 μl AW2 washing solution, centrifuge at 25°C, 20,000 rcf, for 3 min.

[0106] (7) Replace with a new 2 ml collection tube, place in the filter column in (6), spin, and centrifuge at 25°C, 20,000 rcf, for 1 min.

[0107] (8) Let it stand for 2 minutes to allow the ethanol to evaporate.

[0108] (9) Add 50 μl of buffer AE, let stand for 1 min, and centrifuge at 25°C, 6000 rcf, for 1 min.

[0109] 4. Determination of the content and purity of extracted DNA

[0110] Take 2 μl of purified DNA sample, adjust the baseline to 0 with buffer AE, and determine the DNA content and A260 / A280 purity according to the "UV5Nano Ultramicro UV-Vis Spectrophotometer Instructions". If the purity is between 1.8-2.0, the extracted sample meets the requirements.

[0111] Dilute the test sample DNA and negative cell DNA to about 10 ng / μl with Nuclease-Free Water and store them at -20℃ for later use.

[0112] 5. No template control NTC

[0113] Nuclease-Free Water was used as a no-template control.

[0114] 6. PCR reaction system configuration

[0115] Calculate the number of reaction wells required based on the number of positive controls, no-template controls and samples to be tested, and make 2 replicate wells / sample. Number of reaction wells = (1 no-template control NTC + 1 negative control NCS + sample to be tested) × 2

[0116] Calculate the total amount of qPCR MIX required according to the following table: qPCR MIX = (number of reaction wells + 2) × 12 μl (including the loss amount of 2 wells)

[0117] qPCR MIX

[0118] Reaction liquid composition Volume (μl) AceQ U+Universal Probe Master Mix(2×) 10 Upstream primer gag-F (10 μM) 0.8 Downstream primer gag-R (10 μM) 0.8 Probe gag-P (10 μM) 0.4 Total 12

[0119] 7. Sample addition

[0120] Melt each reagent on ice, shake gently to mix, and add samples as shown in the table below.

[0121] Add sample to each reaction well

[0122] Standards to be tested 12μl qPCR MIX + 8μl standard to be tested No template control NTC 12μl qPCR MIX+8μl Nuclease-Free Water Negative Control NCS 12μl qPCR MIX + 8μl negative control NCS purification solution Samples to be tested 12μl qPCR MIX + 8μl purified sample solution

[0123] 8. PCR reaction conditions

[0124]

[0125] 9. Results

[0126] Data Summary

[0127]

[0128] The above data can once again prove that this method can be used in 1×10 7 ~1×10 1 The amplification efficiency within the range of copies / μl is good. The Cp values ​​of NCS and NTC are both higher than the Cp value of the lowest point of the standard curve. The Cp values ​​of negative cells and positive cells are both higher than the lowest point of the standard curve, indicating that the method has good specificity and no non-specific binding amplification. During the method validation process, multiple concentrations will be set up for validation to confirm the method detection limit.

[0129] From the above examples 1 and 2, it can be seen that the present method can be applied to 1×10 7 ~1×10 1 The amplification efficiency within the copies / μl range is good and the specificity is good, and it can be used as a detection method for viral residues in adipose stem cells with high expression of both GLP-1 and FGF21 (qPCR method). During the method validation process, multiple concentrations will be set up for validation to confirm the method detection limit, and the sample test results will be compared with the detection limit to determine whether the sample contains viral residues.

[0130] Example 3

[0131] Overview :Verify that the method of the present invention is suitable for the detection of viral residues in adipose stem cells with high expression of GLP-1 and FGF21 dual factors, and draw a conclusion on the method validation to confirm that the analytical method is suitable for the detection of viral residues in adipose stem cells samples with high expression of GLP-1 and FGF21 dual factors. The validation work was performed according to the following method, and the data of the validation work were summarized and analyzed. The validation results showed that each validation parameter met the preset acceptance criteria, indicating that the method meets the intended use and can be used for the inspection and analysis of viral residues (QPCR method) in adipose stem cells with high expression of GLP-1 and FGF21 dual factors.

[0132] Verification method: The samples used for verification in this example are autologous adipose-derived mesenchymal stem cells that highly express GLP-1 and FGF21. They are autologous adipose-derived mesenchymal stem cells that highly express GLP-1 and FGF21 provided by the applicant's prior patent 201810283803.0. The production information is as follows:

[0133]

[0134] equipment

[0135]

[0136] Reagents and consumables

[0137]

[0138]

[0139] Dilution of Quantitation Standard

[0140] Dilution tube Dilution volume concentration A <![CDATA[10μl 1.64×10 11 copies / μl+6.4μl Nuclease-Free Water]]> <![CDATA[1×10 11 copies / μl]]> B <![CDATA[10μl 1×10 11 copies / μl+90μl Nuclease-Free Water]]> <![CDATA[1×10 10 copies / μl]]> C <![CDATA[10μl 1×10 10 copies / μl+90μl Nuclease-Free Water]]> <![CDATA[1×10 9 copies / μl]]> D <![CDATA[10μl 1×10 9 copies / μl+90μl Nuclease-Free Water]]> <![CDATA[1×10 8 copies / μl]]> ST1 <![CDATA[10μl 1×10 8 copies / μl+90μl Nuclease-Free Water]]> <![CDATA[1×10 7 copies / μl]]> ST2 10μl ST1+90μl Nuclease-Free Water <![CDATA[1×10 6 copies / μl]]> ST3 10μl ST2+90μl Nuclease-Free Water <![CDATA[1×10 5 copies / μl]]> ST4 10μl ST3+90μl Nuclease-Free Water <![CDATA[1×10 4 copies / μl]]> ST5 10μl ST4+90μl Nuclease-Free Water <![CDATA[1×10 3 copies / μl]]> ST6 10μl ST5+90μl Nuclease-Free Water <![CDATA[1×10 2 copies / μl]]>

[0141] Sample ERC preparation: Take 100 μl of the sample to be tested after 10-fold dilution and add it to a 1.5 ml low-absorption centrifuge tube, add 10 μl ST1, mix well, and mark it as sample ERC.

[0142] Preparation of negative control (NCS): Take 100 μl Nuclease-Free Water and add it to a 1.5 ml clean centrifuge tube and mark it as NCS.

[0143] Solution configuration (host cell residual DNA sample pretreatment kit (magnetic bead method), 100preps, Huzhou Shenke, SK030203D100):

[0144] (1) Reagent preparation: All reagents should be equilibrated at room temperature for at least 10 minutes before use.

[0145] (2) Washing Solution A working solution: Add 40 ml of anhydrous ethanol to the newly opened Washing Solution A, mix well, and store at room temperature. The shelf life is tentatively set at 1 year.

[0146] (3) Washing Solution B: Prepare a 70% ethanol solution with anhydrous ethanol using Nuclease-Free Water in a clean reagent bottle. Label it as Washing Solution B and store it at room temperature. The shelf life is tentatively 3 months.

[0147] (4) Proteinase K digestion solution: For each sample, take 10 μl of proteinase K and 100 μl of proteinase K buffer, mix well and use immediately. The volume of the working binding solution can be scaled up or down according to the needs.

[0148] (5) Working Binding Solution: For each sample, take 200 μl of binding solution, 0.2 μl of yeast tRNA and 9 μl of glycogen, mix well and use immediately. The volume of the working binding solution can be scaled up or down according to the needs.

[0149] Sample preparation:

[0150] (1) Sample digestion: (1) Take 100 μl of the test sample and NCS, add 110 μl of the spiked test sample and place in a 1.5 ml clean low-absorption centrifuge tube, add 10 μl of 5 M NaCl solution and 110 μl of proteinase K digestion solution, shake thoroughly for 10 seconds, centrifuge quickly for 5 seconds, and incubate at 55°C for 60 minutes.

[0151] (2) Binding: ① Incubate the magnetic beads at 37℃ for 10min and vortex thoroughly for 5s; ② Remove the sample from the constant temperature metal bath, centrifuge for 30s, add 209μl working binding solution, and vortex thoroughly. After centrifugation, add 200μl isopropanol and 10μl magnetic beads to the sample mixture respectively. Place the centrifuge tube containing the entire mixture on a vortex oscillator for 5min, centrifuge for 10s, and then place it on a magnetic rack; ③ After the solution is clear and the magnetic beads are completely separated, carefully remove the supernatant with a pipette tip.

[0152] (3) Washing: ① Remove the centrifuge tube containing magnetic beads from the magnetic rack, add 700μl of washing solution A working solution, and vortex for 10s; after a split second, return the centrifuge tube to the magnetic rack. After the solution is clear and the magnetic beads are completely separated, remove the supernatant with a pipette tip to complete the first magnetic bead wash; ② Remove the centrifuge tube containing magnetic beads from the magnetic rack, add 700μl of washing solution B, and vortex for 10s; after a split second, return the centrifuge tube to the magnetic rack. After the solution is clear and the magnetic beads are completely separated, remove the supernatant with a pipette tip to complete the second magnetic bead wash; ③ Remove the centrifuge tube from the magnetic rack, open the tube cover and dry it at room temperature for 1 to 3 minutes to remove residual ethanol.

[0153] (4) Elution: ① Add 100 μl of elution solution preheated at 70°C along the wall of the centrifuge tube, vortex gently to mix, incubate at 70°C for 7 min, and vortex to mix again 2 to 3 times during the incubation process; ② After the incubation is completed, centrifuge the centrifuge tube quickly for 1 min and place it on a magnetic separation rack. After the magnetic beads are separated, use a pipette tip to carefully transfer the solution to a clean low-adsorption centrifuge tube. The result is the sample extract to be tested.

[0154] qPCR detection:

[0155] Calculate the number of reaction wells required based on the standard curve, NTC, NCS and number of samples to be tested. Number of reaction wells = (6 standard curves with concentration gradient + 1 NTC + 1 NCS + sample to be tested + sample ERC) ×

[0156] According to the table below, calculate the total amount of qPCR MIX required for this time: qPCR MIX = (number of reaction wells + 2) × 12 μl (including the loss amount of 2 wells)

[0157] (1) qPCR MIX

[0158] Reaction liquid composition Volume (μl) AceQ qPCR Probe Master Mix 10 gag-F (10 μM) 0.8 gag-R (10 μM) 0.8 gag-P (10 μM) 0.4 Total volume 12

[0159] (2) Add samples to each reaction well

[0160] Well number Sample volume Standard curve 12μl qPCR MIX+8μl ST1 / ST2 / ST3 / ST4 / ST5 / ST6 NTC 12μl qPCR MIX+8μl Nuclease-Free Water NCS 12μl qPCR MIX + 8μl NCS extract Samples to be tested 12μl qPCR MIX + 8μl sample extract Sample to be tested ERC 12μl qPCR MIX + 8μl ERC extract of the sample to be tested

[0161] (3) Reaction procedure

[0162]

[0163] (4) Fluorescence quantitative PCR instrument configuration: Set the PCR reaction volume to 20 μl, FAM reporter fluorescent group, and start detection.

[0164] 3.1 Detection limit

[0165] Purpose : The minimum amount of the analyte that can be detected in a quantitative sample.

[0166] Experimental design : Prepare negative cell genome and no template control (NTC), perform 20-well amplification reaction respectively, and use negative cell genome (i.e., NC) to add standard (the same standard plasmid as in Example 1, concentration 1.64×10 11 The PCR reaction system was prepared by diluting the sample to 20, 10, and 5 copies / μl of the standard plasmid, and 20 copies / μl of each concentration were prepared for PCR amplification.

[0167] Dilution tube Dilution volume Concentration (copies / μl) S1 40μl ST6 + 100μl (20ng / μl negative cell genome) + 60μl EASY Dilution 20 S2 20μl ST6 + 100μl (20ng / μl negative cell genome) + 80μl EASY Dilution 10 S3 10μl ST6 + 100μl (20ng / μl negative cell genome) + 90μl EASY Dilution 5

[0168] Acceptable Standards :The detection limit should be less than the two Cp values ​​of NCS and NTC, and the maximum Cp value should be less than the minimum Cp value of NCS and NTC; the RSD of the Cp value of the detection limit sample is ≤5%.

[0169] result :

[0170]

[0171] in conclusion The test results showed that the average Cp values ​​of the signals at 20, 10, and 5 copies / μl were all lower than the two Cp values ​​of NC and NTC, and all 20 replicates could be detected. The RSD of the Cp values ​​of the detection limit samples was less than 5%, which met the acceptance criteria. 5 copies / μl was selected as the detection limit (i.e., 40 copies / test).

[0172] 3.2 Exclusivity

[0173] Purpose : Verify the ability of the analytical method to correctly determine the substance being tested even in the presence of other components (such as impurities, degradation products, excipients, etc.), or that the method specifically detects the substance being tested and cannot be detected when negative substances are present.

[0174] Experimental design : Prepare the test sample, negative cell genome, and the concentration of the detection limit standard determined by the detection limit as the positive control. Prepare 3 parallels for each sample and calculate the average Cp value. The negative cell genome needs to be diluted to about 10 ng / μl for detection. In addition, prepare the quantitative standard spiked sample (2 times the detection limit plasmid standard added to the negative cell genome after lentivirus infection).

[0175] Acceptable Standards:(1) The Cp value of NTC and NCS results is greater than 2 Cp of the detection limit;(2) The Cp value of NC result is greater than 2 Cp of the detection limit;(3) The Cp value of the sample is greater than the detection limit, and adding 2 times the detection limit amount of standard to the sample genome can amplify it, and the Cp value is less than the detection limit.

[0176] result :

[0177]

[0178] in conclusion :The Cp values ​​of the no-template negative control (NTC) and the negative control (NC) were both greater than the Cp values ​​of the positive control (PC) by 2. The test results of the three batches of cell samples were all negative. After adding the positive sample PC, the test results were all positive. The above results all met the acceptance criteria: the sample Cp value was greater than the detection limit, and the 2-fold quantitative limit plasmid standard was added to the sample genome, which could be amplified, and the Cp value was less than the detection limit. This shows that the sample matrix has no effect on the detection.

[0179] 3.3 Durability

[0180] Purpose : To investigate the accuracy and stability of amplification at different times after the sample amplification system is prepared.

[0181] Experimental design : Prepare the detection limit sample (positive control) and two reaction plates for amplification of the positive control, with 3 replicates in each group, and load the sample immediately and after 1 hour (stored at 4°C).

[0182] Acceptable Standards : The Cp value of the positive control RSD ≤ 5%.

[0183] result :

[0184]

[0185] in conclusion :The RSD value of Cp value of loading the sample immediately after preparation and loading the sample 1 hour later (stored at 4℃) is ≤5%, and the measurement result is not affected.

[0186] 3.4 Analysis and evaluation of verification results

[0187] In the inspection and verification of the virus residues (QPCR method) of GLP-1 and FGF21 dual-factor highly expressed adipose stem cells in this embodiment, the detection limit, specificity, and durability of the method were verified under the existing test conditions, and the above verification data all met the acceptance criteria and passed the verification. This shows that the method of the present invention is suitable for the detection of virus residues (QPCR method) of GLP-1 and FGF21 dual-factor highly expressed adipose stem cells.

[0188] The present invention has been described in detail above in conjunction with specific implementations and exemplary examples, but these descriptions cannot be understood as limiting the present invention. Those skilled in the art understand that, without departing from the spirit and scope of the present invention, a variety of equivalent substitutions, modifications or improvements may be made to the technical solution of the present invention and its implementation methods, all of which fall within the scope of the present invention. The scope of protection of the present invention shall be subject to the attached claims.

Claims

1. A method for detecting virus residues in adipose stem cells with high expression of both GLP-1 and FGF21, which detects whether the virus remains by using real-time fluorescence quantitative PCR with gag gene primers.

2. The method according to claim 1, in, The gag gene primers are selected from one or more pairs of the following primers: Ⅰ: Upstream primer: 5'-CCCATGTTTTCAGCATTATCAG-3' Downstream primer: 5′-GTCACTTCCCCTTGGTTCTC-3′; Ⅱ: Upstream primer: 5'-GGGAGCTAGAACGATTCGCA-3' Downstream primer: 5′-TGGGGTGGCTCCTTCTGATA-3′; Ⅲ: Upstream primer: 5'-AGCGTCAGTATTAAGCGGGG-3' Downstream primer: 5′-TGCGAATCGTTCTAGCTCCC-3′; Ⅳ: Upstream primer: 5'-GGAAGATCTGGCCTTCCCAC-3' Downstream primer: 5′-TTATTGTGACGAGGGGTCGC-3′; Ⅴ: Upstream primer: 5'-GGTGCGAGAGCGTCAGTATT-3' Downstream primer: 5′-CAGGCCAGGATTAACTGCGA-3′; Ⅵ: Upstream primer: 5'-TATCAGAAGGAGCCACCCCA-3' Downstream primer: 5′-CTGGGTTCGCATTTTGGACC-3′; Ⅶ: Upstream primer: 5'-ACAGCAATCAGGTCAGCCAA-3' Downstream primer: 5′-GGTTCTCTCATCTGGCCTGG-3′; Ⅷ: Upstream primer: 5'-ACTCTAAGAGCCGAGCAAGC-3' Downstream primer: 5′-CCTTGTCTATCGGCTCCTGC-3′; Ⅸ: Upstream primer: 5'-AAAAAGCACAGCAAGCAGCA-3' Downstream primer: 5′-AAATCTTGTGGGGTGGCTCC-3′; Ⅹ: Upstream primer: 5'-GGCTTTCAGCCCAGAAGTGA-3' Downstream primer: 5′-TCCCATTCTGCAGCTTCCTC-3′; Ⅺ: Upstream primer: 5'-CCAGGCCAGATGAGAGAACC-3' Downstream primer: 5′-CCTAGGGGCCCTGCAATTTT-3′.

3. The method according to claim 1, in, The gag gene primers are the following primers: Ⅰ: Upstream primer: 5'-CCCATGTTTTCAGCATTATCAG-3' Downstream primer: 5′-GTCACTTCCCCTTGGTTCTC-3′.

4. The method according to claim 1, in, Use a probe selected from the following: 5'FAM-AAATCTTGTGGGGTGGCTCCTT-3'; 5'-FAM-AACATCAGAAGGCTGTAGACAAATA-3'; 5'-FAM-AAATTAAAACATATAGTATGGGCAA-3'; 5'-FAM-AGCAGACCAGAGCCAACAGCCCCAC-3'; 5'-FAM-ATATAGTATGGGCAAGCAGGGAGCT-3'; 5'-FAM-ACATCAAGCAGCCATGCAAATGTTA-3'; 5'-FAM-CTATAGTGCAGAACATCCAGGGGCA-3'; 5'-FAM-GATGACAGAAACCTTGTTGGTCCAA-3'; 5'-FAM-CAGGACACAGCAATCAGGTCAGCCA-3'; 5'-FAM-AGCATTATCAGAAGGAGCCACCCCA-3'; 5'-FAM-CAGGAACTACTAGTACCCTTCAGGA-3'.

5. The method according to claim 1, in, The following probes were used: 5'FAM-AAATCTTGTGGGGTGGCTCCTT-3'. The method according to claim 1 , wherein the real-time fluorescence quantitative PCR is performed using a kit.

7. The method according to claim 4, wherein the kit is AceQ Universal U+Probe Master Mix V2 kit, TaqMan TM OpenArray TM Real-Time PCR Master Mix Kit or One Step PrimeScript TM RT-PCR Kit (Perfect RealTime) kit.

8. The method according to any one of claims 1 to 7, wherein the real-time fluorescence quantitative PCR is carried out at 1×10 7 ~1×10 1 copies / μl range.